TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04769258

Intervention type: BIOLOGICAL
Intervention: Pfizer Comirnaty vaccine
Description: COVID 19 vaccines administered to the patients according to the times and modalities established by the Italian National Vaccination Plan. Further vaccines will be evaluated if and when they are available in Italy during the study period.

Intervention type: BIOLOGICAL
Intervention: Pfizer Comirnaty vaccine
Description: COVID 19 vaccines administered to the patients according to the times and modalities established by the Italian National Vaccination Plan. Further vaccines will be evaluated if and when they are available in Italy during the study period.
Study: NCT06279169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Sound
Description: In the Heart sound group, this sound will be played to the newborn 5 minutes before Hep B vaccine administration, during the procedure (at 1 minute) and 5 minutes after Hep B vaccine administration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: White Noise
Description: Musician Osman Orhan's song Bebeğiniz Ağlamasın from his album Kolik will be used for white noise. The volume will be set to 45 db.
Study: NCT05687279

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
Study: NCT05720156

Intervention type: OTHER
Intervention: 99mTc-tilmanocept SPECT/CT scanning
Description: 99mTc-Tilmanocept SPECT/CT allows for visualization of macrophage-specific arterial infiltration

Intervention type: OTHER
Intervention: 99mTc-tilmanocept SPECT/CT scanning
Description: 99mTc-Tilmanocept SPECT/CT allows for visualization of macrophage-specific arterial infiltration
Study: NCT06118840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: True-AI-integrated intracranial aneurysms diagnosis strategy
Description: The True-AI deep-learning based model for intracranial aneurysms detection had a patient-wise sensitivity, lesion-wise sensitivity and specificity of 0.96, 0.87, and 0.80 in the internal validation dataset.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-AI-integrated intracranial aneurysms diagnosis strategy
Description: The Sham-AI deep-learning based model for intracranial aneurysms detection is designed to have a sensitivity close to 0% and a similar specificity to the True-AI. In the internal validation dataset, the Sham-AI had a patient-wise sensitivity, lesion-wise sensitivity, specificity of 0.02, 0.01, and 0.80, respectively.
Study: NCT05459987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle changes
Description: Nutritional advice to progressively integrate a moderate-carbohydrate Mediterranean diet with intermittent fasting 16:8 (5 times/week for 12 weeks).~Personalized exercise prescription and training (3 times per week)~Personalized education and motivational interviewing
Study: NCT06111755

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SmokefreeTXT
Description: National Cancer Institute's SmokefreeTXT is a text message quit smoking program available nationally. Users sign up and choose a target quit date that is within 2 weeks of their signup date. Users receive 3-5 text messages per day for up to 2 weeks pre-quit and 6 weeks post-quit. The quit date can be reset as often as needed by the user.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SmokefreeTXT
Description: National Cancer Institute's SmokefreeTXT is a text message quit smoking program available nationally. Users sign up and choose a target quit date that is within 2 weeks of their signup date. Users receive 3-5 text messages per day for up to 2 weeks pre-quit and 6 weeks post-quit. The quit date can be reset as often as needed by the user.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartband
Description: A smartband that will track smoking in real-time and ask the individual to confirm/deny smoking. Participants will be asked to wear the smartband during their waking hours and to charge it overnight.
Study: NCT05955651

Intervention type: DIAGNOSTIC_TEST
Intervention: Peritoneal washings
Description: Peritoneal washing will be done at designated point in the surgical procedure. one hundred cc of normal saline, will be used to irrigate the peritoneal cavity. Samples of the fluid will be collected, with the goal to collect as much fluid as possible for the study, with minimum of 60 cc should be collected. Samples will be sent to the pathology lab.~1. First washing will be collected after obtaining entry into the peritoneal cavity with placement of the first laparoscopic trocar, before any manipulation of the uterus.~2. Second washing will be done after the hysterectomy and containment of the uterus in the bag.~3. Third washing will be collected after scalpel morcellation of the uterus in the containment bag, extraction and closure of the vaginal cuff.
Study: NCT05881590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid pulmonary rehabilitation
Description: Technology-enabled 8-week pulmonary rehabilitation programme using the Active+me REMOTE App
Study: NCT06444399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: 6 mg administered orally twice daily for 24 weeks.
Study: NCT04690673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1 g oral paractamol

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Paracetamol concentration measurements and lipidomic assessment
Description: Paracetamol concentration is measured from saline-, urine-, venous blood- and fingerprick- samples at timely intervals. Also serum lipidomic assessment is performed from venous blood samples.
Study: NCT06037863

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo bladder filling prior to CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Procedure
Description: Undergo bladder emptying prior to CT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT05944731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: Continuous Glucose Monitoring (CGM) device is a small electronic tool that you put on your skin, and it tells you the amount of glucose in your body. It is different from a finger prick glucose machine in that you do not need to prick your finger to get some blood to put on the reader paper like you have to do for a finger prick glucose machine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: Continuous Glucose Monitoring (CGM) device is a small electronic tool that you put on your skin, and it tells you the amount of glucose in your body. It is different from a finger prick glucose machine in that you do not need to prick your finger to get some blood to put on the reader paper like you have to do for a finger prick glucose machine.
Study: NCT05633394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtaCor StealthTrac Lead
Description: Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
Study: NCT05303051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application Validation
Description: After creating accounts, participants in both groups will download the Azumio Instant Diabetes Test and provide a Photoplethysmography (PPG) waveforms by placing their index finger over their smartphone camera for 20 seconds to provide PPG waveform data for the study .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application Validation
Description: After creating accounts, participants in both groups will download the Azumio Instant Diabetes Test and provide a Photoplethysmography (PPG) waveforms by placing their index finger over their smartphone camera for 20 seconds to provide PPG waveform data for the study .
Study: NCT05069623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.2129
Description: 0.3 mg, 1 mg or 3 mg on Day 0 and Day 21 or 3 mg on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.2129
Description: 0.3 mg, 1 mg or 3 mg on Day 0 and Day 21 or 3 mg on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.2210
Description: 3 doses (dose to be determined) on Day 0 and Day 21 or highest dose (TBD) on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.2210
Description: 3 doses (dose to be determined) on Day 0 and Day 21 or highest dose (TBD) on Day 0
Study: NCT06281236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone according to the participant's pre-trial dose, symptoms and inflammatory biomarkers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-62
Description: SPI-62 administered once daily.
Study: NCT05937295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fusion-VAC-XS15
Description: FusionVAC-22 peptide will be administered subcutaneously (s.c.) adjuvanted with the Toll-like receptor 1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1).~Vaccination will take place every 4 weeks at the beginning of Cycle 1 and 2. A total of two vaccinations are planned.~After 11 months a booster vaccination can be applied depending on T-cell responses.~Immune checkpoint inhibition (ICI):~Atezolizumab (TecentriqTM, Roche Pharma AG) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that targets PD-L1 and will be applied intravenously (i.v.).~The anti-PD-L1 antibody Atezolizumab (TecentriqTM) 1680 mg will be applied every 4 weeks as a 30-minute infusion (60-minute first dose) starting on day 15 after the first vaccination. Anti-PD-L1 treatment will be continued after the end of vaccination phase throughout the complete study period until End of Treatment (EOT) or until disease progression or other reasons for study termination.
Study: NCT05225558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delpazolid
Description: BID, PO
Study: NCT06580548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHW-supported telerehabilitation
Description: Participants will receive the Mobile Rehab mobile software, which allows participants to be prescribed personalized rehabilitation strengthening video regimens electronically based on respondent-indicated mobility and activities of daily living functionality

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will be provide a list of local social services resources, including mental health, that participants can use . A callback number will be provided if they have any questions about the services.
Study: NCT06493617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Mobilization
Description: The technique is used to mobilize a specific cervical or upper thoracic segment (C2-C3 through T3-T4) in a posterior to anterior direction. The therapist gently applies pressure in an anteroposterior direction in the plane of the facet joint to assess mobility, resistance, end feel, and pain provocation. Gentle oscillations can be used to either inhibit pain (grades I and II) or restore motion (grades III and IV). Slight variations in depth and direction of force can be used to optimize the therapeutic effects of this technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy treatment
Description: tendon gliding exercises, median nerve gliding exercise, strengthening exercises for 60 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy treatment
Description: tendon gliding exercises, median nerve gliding exercise, strengthening exercises for 60 minutes
Study: NCT05619185

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CRAFT Web-Based Intervention
Description: Session 1 addresses CPs' mental health issues and drinking. CPs select reasons why they are seeking help and steps they will take towards those goals. Session 2 is focused on improving their relationship through communication exercises. Session 3 is focused on functional analysis of their partner's drinking, and how to positively reinforce their partner's sobriety and negatively reinforce their drinking. Finally, Session 4 focuses on continuing self-care and talking with their partner about their concerns while interacting with them in healthy ways. The WBI contains audio, video, text, and exercises that utilize digital storytelling and vignettes to convey teaching points - a method utilized by the military to address stigma and increase treatment utilization. Actresses portrayed different experiences that the CP may be going through and modeled skills. CPs clicked on the vignette that they most connected with and followed that character across all the sessions.
Study: NCT05225558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: IV infusion per 2020 IDSA guideline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vancomycin
Description: IV infusion per 2020 IDSA guideline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Delpazolid
Description: BID, PO
Study: NCT06115070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: intravenous alteplase(0.9 mg/kg;maximum dose, 90mg; 10% administered as a 1-minute bolus,the remaining infused over 1 hour)
Study: NCT05619185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRAFT Web-Based Intervention
Description: Session 1 addresses CPs' mental health issues and drinking. CPs select reasons why they are seeking help and steps they will take towards those goals. Session 2 is focused on improving their relationship through communication exercises. Session 3 is focused on functional analysis of their partner's drinking, and how to positively reinforce their partner's sobriety and negatively reinforce their drinking. Finally, Session 4 focuses on continuing self-care and talking with their partner about their concerns while interacting with them in healthy ways. The WBI contains audio, video, text, and exercises that utilize digital storytelling and vignettes to convey teaching points - a method utilized by the military to address stigma and increase treatment utilization. Actresses portrayed different experiences that the CP may be going through and modeled skills. CPs clicked on the vignette that they most connected with and followed that character across all the sessions.
Study: NCT05805761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: A bicarbonate jet will be used to remove the biofilm from the surface of the teeth.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: A bicarbonate jet will be used to remove the biofilm from the surface of the teeth.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic Therapy
Description: aPDT will be performed before each cleaning/prophylaxis session, only in one of the groups. Participants will swish with the photosensitizer erythrosine for 1 min of pre-irradiation time, so that the drug can stain all the bacterial biofilm. The D-2000 LED (DMC) will be applied, emitting at a wavelength of ʎ = 430-490 nm and 900-1100 mW/cm2. Irradiation will be performed until the biofilm of the cervical region is illuminated for 2 min per point. Each irradiation point will be approximately 0.4 cm2.
Study: NCT05349149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab/Actemra® (Roche)
Description: The infusion of tocilizumab will antagonize IL-6 signaling for the duration of the study, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 9%
Description: The infusion of saline will serve as placebo for tocilizumab, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
Study: NCT05874895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage
Description: Manual lymphatic drainage massage involves gently manipulating specific areas of the body to help lymph move to an area with working lymph vessels.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care provided for patients in septic shock.
Study: NCT06509425

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: salpingectomy during caesarean section
Description: Salpingectomy will be done by clamping, division and ligation using adsorbable suture material (2-0 Vicryl) and excising the tube till it's isthmic part by scissors.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tubal ligation during caesarean section
Description: Tubal ligation will be done by Parkland technique. An opening is made in an avascular section of the mesosalpinx by electrocautery. Two absorbable suture ties (2-0 Vicryl) are passed through the opening and used to ligate the proximal and distal ends of the segment (at least 2 cm) which will get excised by scissors.
Study: NCT05535803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olfactory mucosa-derived mesenchymal stem cells
Description: Autologous olfactory mucosa-derived mesenchymal stem cells

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patients treated according to current clinical protocols
Description: Patients treated according to current clinical protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients treated according to current clinical protocols
Description: Patients treated according to current clinical protocols
Study: NCT06319365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: the yoga practice of the group should completed at the end of 12 weeks
Study: NCT05543980

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 33ºC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leg heat therapy device
Description: The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 42ºC.
Study: NCT06053983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Turbox CRP kit
Description: Quantitative estimation of hs-CRP will be conducted at the beginning of the study and after the treatment period using the Turbox CRP kit, which employs turbidimetry as the method of measurement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Turbox CRP kit
Description: Quantitative estimation of hs-CRP will be conducted at the beginning of the study and after the treatment period using the Turbox CRP kit, which employs turbidimetry as the method of measurement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg,
Description: The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin 40 mg
Description: The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
Study: NCT05999773

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Start of SGLT-2 inhibitors to treat diabetes according diabetology indications.
Study: NCT06340893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will participate in cardiovascular, agility, balance, strength and coordination training.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Restful Play
Description: This group will engage in restful play activities such as coloring and playing with legos.
Study: NCT05348239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Copper Chlorophyllin
Description: Sodium-copper-chlorophyllin (CHL) is a phytopharmaceutical drug obtained from green plant pigment, chlorophyll. Chlorophyllin scavenges radiation-induced free radicals and reactive oxygen species. It is used as a food colorant and OTC in the USA, Japan, Australia and China for many years for a variety of health benefits including prevention of body odour in geriatric patients, enhanced wound healing, antibacterial action, prevention of cancer in the high-risk populations exposed to hepatocarcinogen aflatoxin B1, treatment of faecal incontinence etc. Studies have shown that CHL has immunostimulatory, anti-inflammatory and antiviral effects in addition to antioxidant and radioprotective properties. It increases the expression of a transcription factor (protein) Nrf2 which improves lymphocyte survival and enables efficient detoxification after exposure to radiation. The duration of therapy will be up to 6 months depending upon the response of participants.
Study: NCT05248880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: Intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: Intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular Injection